Who is sponsoring NCT00749580?

NCT00749580 is sponsored by University of South Florida.

What condition does NCT00749580 study?

NCT00749580 studies Virus Diseases, HIV.

What drugs are being tested in NCT00749580?

Interventions: Switch NRTIs as a Backbone to Raltegravir.

What is the status of NCT00749580?

NCT00749580 is currently COMPLETED.

Last reviewed 2014-12-02 · How we verify

A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen

NCT00749580 NA COMPLETED Results posted

The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.

Details

Lead sponsor	University of South Florida
Phase	NA
Status	COMPLETED
Enrolment	46
Start date	2008-11
Completion	2011-07

Conditions

Virus Diseases
HIV

Interventions

Switch NRTIs as a Backbone to Raltegravir

Primary outcomes

Number of Patients With Suppressed Viral Load(<75 Copies/ml)in Raltegravir 400 mg Bid vs. NRTI Backbone, Each in Combination of Boosted PI Regimen — at 24weeks for each patient
Number of patients with virologic suppression\< 75 copies/ ml at 24 wk,in raltegravir 400 mg bid vs. NRTI backbone, each in combination of boosted PI regimen.

Countries

United States